Clinical trial NCT04833049: Study to Evaluate Absorption, Metabolism, and Excretion, of TAK-994 in 6 Healthy Male Adults
Official title: A Phase 1 Study to Assess Absolute Bioavailability of TAK-994 and to Characterize Mass Balance, Pharmacokinetics, Absorption, Metabolism, and Excretion of [14C]TAK-994 in Male Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Volunteers
Keywords: Drug Therapy
Lead sponsor: Takeda
Sponsor class: INDUSTRY
First posted: 2021-04-06
Enrollment: 6
Sex: MALE
Minimum age (years): 19
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SEQUENTIAL
Primary purpose: OTHER

Brief summary: The aim of this study is to understand how TAK-994 is processed by the body.

This study will require participants to stay at the clinical research unit for 3 weeks to be monitored after receiving TAK-994.

Detailed description: The drug being tested in this study is called TAK-994. TAK-994 is being tested in healthy male participants. This study will characterize how TAK -994 is absorbed, metabolize, excreted by the body, after single oral administration by collecting plasma, urine, and feces samples for testing.

The study will enroll approximately 6 participants. The study consists of 2 parts: Part A and Part B.

In Part A, all participants will receive TAK-994 as tablet and \[14C\]TAK-994 as intravenous infusion. In Part B, all participants will receive a single dose of \[14C\]TAK-994 as an oral suspension.

This single-center trial will be conducted in the United States. The overall time to participate in this study is approximately 67 days, including a 28-day screening period plus approximately 30 days for follow up.

Eligibility criteria: Inclusion Criteria:

1. Body mass index (BMI) greater than or equal to (\>=) 18.0 and less than (\<) 32.0 kilogram per square meter (kg/m\^2) at the screening.
2. Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs or electrocardiograms (ECGs), as deemed by the Investigator or designee.
3. Continuous non-smoker who has not used nicotine-containing products for at least 90 days prior to the first dosing and throughout the study, based on participant self-reporting.
4. Agrees to comply with any applicable contraceptive requirements of the protocol.
5. Agree not to donate sperm from the first dosing until 95 days after the last dosing.
6. Agree and able to remain in the clinical research unit (CRU) for the duration of the study.
7. Understands the study procedures in the ICF, and be willing and able to comply with the protocol.
8. Able to swallow oral suspensions.

Exclusion Criteria:

1. Mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.
2. History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the Investigator or designee.
3. History or presence of gastritis, gastrointestinal tract, hepatic disorder, cholecystectomy, history of treated or untreated Helicobacter pylori, ulcer disease, or other clinical condition which, in the opinion of the Investigator or designee, may affect the absorption, distribution, metabolism, or elimination of study drug.
4. History of any illness that, in the opinion of the Investigator or designee, might confound the results of the study or poses an additional risk to the participant by their participation in the study.
5. History or presence of alcoholism or drug abuse within the past 2 years prior to the first dosing per the Diagnostic and Statistical Manual of Mental Disorders-V criteria.
6. History or presence of hypersensitivity or idiosyncratic reaction to the study drug or related compounds.
7. Current or past history of epilepsy, seizure, convulsion, tremor, or related symptoms.
8. Positive urine drug or alcohol results at screening or check-in.
9. Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV).
10. Seated blood pressure is less than 90/40 millimeter of mercury (mmHg) or greater than 140/90 mmHg at screening.
11. Seated heart rate is lower than 45 beats per minute (bpm) or higher than 100 bpm at screening.
12. Orthostatic vital sign results with a decrease in systolic greater than (\>) 20 mmHg or decrease in diastolic \>10 mmHg, and increase in pulse of \>20 bpm.
13. QT interval corrected for heart rate using Frederica's equation (QTcF) is \>450 milliseconds (msec) or ECG findings are deemed abnormal with clinical significance by the Investigator or designee at screening.
14. Liver function tests including alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) \>1.5\*upper limit of normal (ULN) at screening or check-in.
15. Estimated creatinine clearance \<90 milliliter per minute (mL/min) at screening.
16. Tattoo(s) or scarring at or near the site of IV infusion or any other condition which may interfere with infusion site examination, in the opinion of the Investigator of designee;
17. Infrequent bowel movements (less than approximately once per day) within 30 days prior to dosing.
18. Recent history of abnormal bowel movements, such as diarrhea, loose stools, or constipation, within 2 weeks of dosing.
19. Lactose intolerance.
20. Has received radiolabeled substances or has been exposed to radiation sources within 12 months of first dosing or is likely to receive radiation exposure or radioisotopes within 12 months of last dosing such that participation in this study would increase their total exposure beyond the recommended levels considered safe (that is, weighted annual limit recommended by the International Commission on Radiological Protection \[ICRP\] of 3000 millirem \[mrem\]).
21. Unable to refrain from or anticipates the use of:

    * Any drug, including prescription and non-prescription medications, herbal remedies, or vitamin supplements within 14 days prior to the first dosing and throughout the study. Thyroid hormone replacement medication may be permitted if the participant has been on the same stable dose for the immediate 3 months prior to first study drug administration. After first dosing and throughout the study, ibuprofen (up to 1.2 gram \[g\] per 24 hours) may be administered at the discretion of the Investigator or designee. Milk of Magnesia (that is, magnesium hydroxide) (less than or equal to \[\<=\] 60 milliliter \[mL\] per day) may be administered from Day 3 of each study part, at discretion of the Investigator, to ensure defecation.
    * Any drugs known to be significant inducers or inhibitors of Cytochrome P450 3A4 (CYP3A4) enzymes and/or P-glycoprotein (P-gp), including St. John's Wort, within 28 days prior to the first dosing and throughout the study, including the follow-up period. Appropriate sources (example, Flockhart TableTM) will be consulted to confirm lack of pharmacokinetics (PK)/pharmacodynamics interaction with study drug.
22. Participation in another clinical study treated with the radiolabeled drug within 6 months prior to the first dosing.
23. Participants has a history of alcohol consumption exceeding 2 standard drinks per day on average (1 glass is approximately equivalent to the following: beer \[354 mL/12 Ounce \[oz\]\], wine \[118 mL/4 oz\], or distilled spirits \[29.5 mL/1 oz\] per day).
24. Participant consumes excessive amounts, defined as greater than 4 servings (1 serving is approximately equivalent to 120 mg of caffeine), of coffee, tea, cola, energy drinks, or other caffeinated beverages per day.
25. Has been on a diet incompatible with the on-study diet, in the opinion of the Investigator or designee, within the 30 days prior to the first dosing and throughout the study.
26. Donation of blood or significant blood loss within 56 days prior to the first dosing.
27. Plasma donation within 7 days prior to the first dosing.
28. Participation in another clinical study within 30 days or 5 half-lives prior to the first dosing. The 30-day window or 5 half-lives will be derived from the date of the last blood collection or dosing, whichever is later, in the previous study to Day 1 of Part A of the current study.

Primary outcomes:
measure: Part A: Percent Absolute Bioavailability (%F) for TAK-994
timeFrame: Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose
measure: Part B: Percentage of Total Radioactivity (TRA) in Urine (Cum Percent [%] Dose [UR]) Relative to the Administered Radioactive Dose
timeFrame: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
measure: Part B: Percentage of TRA in Feces (Cum%Dose[FE]) Relative to the Administered Radioactive Dose
timeFrame: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
measure: Part B: Percentage of TRA Recovered in in the Urine and Feces Combined (Combined Cum%Dose) Relative to the Administered Radioactive Dose
timeFrame: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
Secondary outcomes:
measure: Part A, Ceoi: Plasma Concentration at the end of Infusion for [14C]TAK-994
timeFrame: Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose
measure: Part A, CL: Total Clearance for [14C]TAK-994
timeFrame: Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose
measure: Part A, Vss: Volume of Distribution at Steady State After Intravenous Administration for [14C]TAK-994
timeFrame: Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose
measure: Part A, AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-994 and [14C]TAK-994
timeFrame: Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose
measure: Part A, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-994 and [14C]TAK-994
timeFrame: Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose
measure: Part A, t(1/2z): Terminal Disposition Half-life for TAK-994 and [14C]TAK-994
timeFrame: Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose
measure: Part A, Cmax: Maximum Observed Plasma Concentration for TAK-994
timeFrame: Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose
measure: Part A, Tmax: Time to Reach the Maximum Plasma Concentration for TAK-994
timeFrame: Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose
measure: Part B, Cmax: Maximum Observed Plasma Concentration for TAK-994
timeFrame: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
measure: Part B, Tmax: Time to Reach the Maximum Plasma Concentration for TAK-994
timeFrame: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
measure: Part B, AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-994
timeFrame: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
measure: Part B, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-994
timeFrame: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
measure: Part B, t(1/2z): Terminal Disposition Half-life for TAK-994
timeFrame: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
measure: Part B, Cmax: Maximum Observed Plasma and Whole Blood TRA Concentration for TAK-994
timeFrame: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
measure: Part B, Tmax: Time to Reach the Maximum Plasma and Whole Blood TRA Concentration (Cmax) for TAK-994
timeFrame: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
measure: Part B, AUClast: Area Under the Plasma and Whole Blood TRA Concentration-time Curve From Time 0 to Last Quantifiable Concentration for TAK-994
timeFrame: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
measure: Part B, AUC∞: Area Under the Plasma and Whole Blood TRA Concentration-time Curve From Time 0 to Infinity for TAK-994
timeFrame: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
measure: Part B, AUCt: Area Under the Plasma and Whole Blood TRA Concentration-time Curve From Time 0 to Time t for TAK-994
timeFrame: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
measure: Part B, t(1/2z): Terminal Disposition Phase Half-life of Plasma and Whole Blood TRA Concentration for TAK-994
timeFrame: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
Other outcomes:
Locations:
city: Lincoln
country: United States
facility: Celerion
state: Nebraska
Study officials:
affiliation: Takeda
name: Study Director
role: STUDY_DIRECTOR
References: